Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Atossa Therapeutics Inc ATOS

Healthcare Biotechnology
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen... see more

Recent & Breaking News (NDAQ:ATOS)

Atossa Genetics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2019

GlobeNewswire January 28, 2019

Thinking about buying stock in American Airlines, Aurora Cannabis Inc, Atossa Genetics, Chesapeake Energy or Tilray?

PR Newswire January 10, 2019

56 Biggest Movers From Yesterday

Benzinga.com  January 10, 2019

Mid-Afternoon Market Update: SMART Global Holdings Falls On Downbeat Earnings; Diebold Nixdorf Shares Jump

Benzinga.com  January 9, 2019

45 Stocks Moving In Wednesday's Mid-Day Session

Benzinga.com  January 9, 2019

Mid-Day Market Update: Crude Oil Up 5%; Constellation Brands Shares Plunge

Benzinga.com  January 9, 2019

Atossa Genetics Announces Successful Completion and Final Results from Male Phase 1 Study of Topical Endoxifen

GlobeNewswire January 9, 2019

Detailed Research: Economic Perspectives on American Airlines Group, Sandstorm Gold, Kala Pharmaceuticals, Adecoagro S.A, Novagold Resources, and Atossa Genetics — What Drives Growth in Today's Competitive Landscape

GlobeNewswire December 28, 2018

The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

Benzinga.com  December 21, 2018

Edison issues outlook on Atossa Genetics (ATOS)

GlobeNewswire December 7, 2018

Thinking about buying stock in Atossa Genetics, Cronos Group, New Age Beverages Co, Tesaro Inc. or 22nd Century Group Inc.?

PR Newswire December 4, 2018

Explosion of Latest Clinical Studies and Results Reinvigorating Immunotherapy Market

PR Newswire December 4, 2018

Atossa Genetics Announces FDA Approval  of Endoxifen for “Expanded Access” as Preoperative Systemic Endocrine Therapy for a U.S. Breast Cancer Patient

GlobeNewswire December 3, 2018

The Daily Biotech Pulse: Mallinckrodt Faces FDA Panel, Reshape's Earnings, Vapotherm To Debut

Benzinga.com  November 14, 2018

Atossa Genetics Announces Third Quarter 2018 Financial Results And Provides Company Update

GlobeNewswire November 13, 2018

The Daily Biotech Pulse: Viking's Fatty Liver And Cholesterol Drug, Cyclacel Loss Narrows, Eton's Debut

Benzinga.com  November 13, 2018

Atossa Genetics Completes Enrollment in Phase 2 Study of Topical Endoxifen in Women with Mammographic Breast Density

GlobeNewswire October 11, 2018

The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares

Benzinga.com  September 18, 2018

Atossa Genetics Announces Preliminary Results from Male Phase 1 Study of Topical Endoxifen

GlobeNewswire September 13, 2018

Atossa Genetics to Host Conference Call to Announce Preliminary Results from Male Phase 1 Study of Topical Endoxifen Thursday, September 13, 2018 at 10 am EDT

GlobeNewswire September 12, 2018